However, despite the strong scientific rationale and impressive prolongation of progression-free survival with maintenance PARP inhibitor monotherapy in patients with platinum-sensitive, BRCA1/2-mutant ovarian cancers18,19, acquired resistance to PARP inhibitors and the limited therapeutic efficacy of PARP inhibitors in patients with platinum-resistant cancers remain a substantial clinical challenge20. Here, BRCA1 is linked to cancer.